Drug Profile
Research programme: photodynamic therapeutics - Genisphere/University of Pennsylvania
Alternative Names: Photodynamic 3DNA® therapeuticsLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Genisphere; University of Pennsylvania
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 22 Mar 2016 Genisphere's 3DNA® is available for licensing as of 22 Mar 2016. http://www.genisphere.com/partnering-contact
- 22 Mar 2016 Preclinical development in Breast cancer in USA (unspecified route)